Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
Julie Vassart, Research Assistant at University of Namur, shared a post on LinkedIn:
“I am delighted to share that I will present three posters at the 34th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026) in Paris.
- On Sunday 12 July | 13:45 – 14:45 CEST
PB1279: Impact of clinically relevant plasma thresholds for edoxaban on DOAC Dipstick performance.
This poster examines how the plasma thresholds used to define clinically relevant edoxaban levels affect the performance of the DOAC Dipstick, a point-of-care urine test designed to detect direct factor Xa inhibitors (DXI) and direct thrombin inhibitors (DTI).
PB1216: Impact of the prevalence of clinically relevant edoxaban plasma levels on DOAC Dipstick performance.
This second poster showcases how the prevalence of clinically relevant edoxaban plasma levels influences the performance of the DOAC Dipstick, thereby highlighting the impact of the clinical setting and adherence to DOAC therapy on this point-of-care test.
- On Monday 13 July | 13:45 – 14:45 CEST
PB2823: Interference of abelacimab and osocimab with routine and specific coagulation assays.
This poster documents the impact of abelacimab (a monoclonal antibody that blocks FXI in an inactive conformation) and osocimab (an FXIa inhibitor) on a panel of routine and specific laboratory coagulation assays.
I would like to thank the teams at Doasense, Karolinska Institutet, and Karolinska University Hospital.
Special thanks go to Job Harenberg, Simone Mangold, Jovan Antovic, and Henrik von Horn.
I would also like to warmly thank my colleagues at the University of Namur, the Namur Research Institute for Life Sciences, and the Clinical Pharmacology and Toxicology Research Unit, especially Laure Morimont, and Hélène Dumont for their continued support.
Last but not least, a special thank-you goes to my mentor, Jonathan Douxfils, for his guidance and the many discussions that have shaped these works.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure
-
Aug 13, 2026, 08:11Cristiana Coneru: How the Gut Microbiome Influences Venous Thrombosis
-
Aug 13, 2026, 06:36Steffen Uffenorde: Improving Access to Automated Red Cell Exchange in SCD
-
Aug 12, 2026, 23:16A Rare Case of Glanzmann Thrombasthenia and VWD in the Same Patient – Glanzmann’s Research Foundation
-
Aug 12, 2026, 23:15Samwel Mikaye: Recognizing Symptoms, Risk Factors and Warning Signs of DVT